Vanguard Group Inc. Has $472.22 Million Stock Position in TG Therapeutics, Inc. $TGTX

Vanguard Group Inc. boosted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 2.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,841,002 shares of the biopharmaceutical company’s stock after buying an additional 319,703 shares during the period. Vanguard Group Inc. owned approximately 0.10% of TG Therapeutics worth $472,220,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of TGTX. Danske Bank A S bought a new stake in shares of TG Therapeutics in the third quarter valued at approximately $25,000. Optiver Holding B.V. increased its position in TG Therapeutics by 3,485.7% during the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 732 shares during the period. Bessemer Group Inc. raised its stake in TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 486 shares during the last quarter. Stone House Investment Management LLC acquired a new position in TG Therapeutics during the 3rd quarter valued at $36,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in TG Therapeutics by 86.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 573 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Trading Up 1.1%

Shares of TGTX stock opened at $36.10 on Wednesday. The firm has a fifty day moving average of $32.24 and a 200-day moving average of $31.49. The stock has a market cap of $5.53 billion, a price-to-earnings ratio of 13.03 and a beta of 1.68. TG Therapeutics, Inc. has a 52-week low of $25.28 and a 52-week high of $40.99. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.29 and a current ratio of 4.10.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.06). TG Therapeutics had a net margin of 72.56% and a return on equity of 101.12%. On average, equities research analysts forecast that TG Therapeutics, Inc. will post 1.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on TGTX shares. The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research report on Thursday, January 15th. JPMorgan Chase & Co. reduced their target price on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Zacks Research downgraded TG Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, May 1st. Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a research note on Wednesday, January 14th. Finally, Weiss Ratings raised TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $50.00.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.